Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

The randomized phase III ELOQUENT‐2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma. ELd reduced the risk of disease progression/death by 30% versus Ld (hazard ratio...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San‐Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth, Grosicki, Sebastian, Spicka, Ivan, Walter‐Croneck, Adam, Magen, Hila, Mateos, Maria‐Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickardt, Eric, Poulart, Valerie, Sheng, Jennifer, Sy, Oumar, Katz, Jessica, Singhal, Anil, Richardson, Paul
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Haematological Malignancy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6084289/
https://ncbi.nlm.nih.gov/pubmed/28677826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14787
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares